(CZR) Caesars Entertainment - Overview
Stock: Casino, Hotel, Sportsbook, iGaming, Dining
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 50.3% |
| Relative Tail Risk | -6.31% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.90 |
| Alpha | -65.44 |
| Character TTM | |
|---|---|
| Beta | 1.546 |
| Beta Downside | 1.434 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.61% |
| CAGR/Max DD | -0.39 |
Description: CZR Caesars Entertainment January 08, 2026
Caesars Entertainment, Inc. (NASDAQ:CZR) is a U.S.-based gaming and hospitality operator that owns, leases, brands, or manages casino-resort properties across 18 states, offering slot machines, video lottery terminals, e-tables, table games (including poker), and hotel accommodations. The company also runs retail and online sports-betting platforms in 32 North American jurisdictions and iGaming services in five, complemented by a portfolio of dining, nightlife, and entertainment venues, as well as staffing and management services.
As of the most recent quarterly filing (Q3 2024), Caesars reported total revenue of $4.2 billion, with adjusted EBITDA of $1.1 billion and a same-store net gaming revenue (NSGR) growth of +4.2% year-over-year, reflecting resilience in its core casino operations despite a modest dip in discretionary travel. The balance sheet carries roughly $7.5 billion of net debt, offset by a cash-plus-investments position of $1.3 billion, yielding a net debt-to-EBITDA ratio near 6.8×, a metric investors watch closely for leverage risk.
Key macro drivers for Caesars include U.S. consumer discretionary spending trends, tourism flows to gaming hubs, and the rapid expansion of regulated online sports-betting, which has grown at an estimated compound annual growth rate of 15% since 2020. Monitoring state-level licensing activity and the Federal Reserve’s interest-rate trajectory is essential, as they directly affect both foot traffic and the cost of capital for the highly leveraged business. For a deeper, data-rich perspective on how these factors are pricing into the stock, a quick look at ValueRay’s analyst toolkit can be a useful next step.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -241.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 1.48 > 1.0 |
| NWC/Revenue: -4.34% < 20% (prev -3.26%; Δ -1.08% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.33b > Net Income -241.0m |
| Net Debt (24.02b) to EBITDA (3.60b): 6.68 < 3 |
| Current Ratio: 0.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (207.0m) vs 12m ago -3.72% < -2% |
| Gross Margin: 47.15% > 18% (prev 0.52%; Δ 4663 % > 0.5%) |
| Asset Turnover: 35.05% > 50% (prev 34.19%; Δ 0.87% > 0%) |
| Interest Coverage Ratio: 0.93 > 6 (EBITDA TTM 3.60b / Interest Expense TTM 2.34b) |
Altman Z'' -0.07
| A: -0.02 (Total Current Assets 1.73b - Total Current Liabilities 2.23b) / Total Assets 31.90b |
| B: -0.10 (Retained Earnings -3.05b / Total Assets 31.90b) |
| C: 0.07 (EBIT TTM 2.18b / Avg Total Assets 32.43b) |
| D: -0.11 (Book Value of Equity -2.96b / Total Liabilities 27.93b) |
| Altman-Z'' Score: -0.07 = B |
Beneish M -3.06
| DSRI: 0.90 (Receivables 426.0m/469.0m, Revenue 11.37b/11.27b) |
| GMI: 1.10 (GM 47.15% / 52.05%) |
| AQI: 1.00 (AQ_t 0.49 / AQ_t-1 0.49) |
| SGI: 1.01 (Revenue 11.37b / 11.27b) |
| TATA: -0.05 (NI -241.0m - CFO 1.33b) / TA 31.90b) |
| Beneish M-Score: -3.06 (Cap -4..+1) = AA |
What is the price of CZR shares?
Over the past week, the price has changed by -0.87%, over one month by -13.67%, over three months by +7.10% and over the past year by -43.63%.
Is CZR a buy, sell or hold?
- StrongBuy: 10
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CZR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.1 | 56.5% |
| Analysts Target Price | 32.1 | 56.5% |
| ValueRay Target Price | 15.1 | -26.2% |
CZR Fundamental Data Overview February 05, 2026
P/S = 0.3761
P/B = 1.1096
P/EG = 3.2616
Revenue TTM = 11.37b USD
EBIT TTM = 2.18b USD
EBITDA TTM = 3.60b USD
Long Term Debt = 11.68b USD (from longTermDebt, last quarter)
Short Term Debt = 114.0m USD (from shortTermDebt, last quarter)
Debt = 24.86b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 24.02b USD (from netDebt column, last quarter)
Enterprise Value = 28.30b USD (4.28b + Debt 24.86b - CCE 836.0m)
Interest Coverage Ratio = 0.93 (Ebit TTM 2.18b / Interest Expense TTM 2.34b)
EV/FCF = 70.22x (Enterprise Value 28.30b / FCF TTM 403.0m)
FCF Yield = 1.42% (FCF TTM 403.0m / Enterprise Value 28.30b)
FCF Margin = 3.54% (FCF TTM 403.0m / Revenue TTM 11.37b)
Net Margin = -2.12% (Net Income TTM -241.0m / Revenue TTM 11.37b)
Gross Margin = 47.15% ((Revenue TTM 11.37b - Cost of Revenue TTM 6.01b) / Revenue TTM)
Gross Margin QoQ = 36.98% (prev 51.08%)
Tobins Q-Ratio = 0.89 (Enterprise Value 28.30b / Total Assets 31.90b)
Interest Expense / Debt = 2.34% (Interest Expense 581.0m / Debt 24.86b)
Taxrate = 21.0% (US default 21%)
NOPAT = 1.72b (EBIT 2.18b * (1 - 21.00%))
Current Ratio = 0.78 (Total Current Assets 1.73b / Total Current Liabilities 2.23b)
Debt / Equity = 6.57 (Debt 24.86b / totalStockholderEquity, last quarter 3.78b)
Debt / EBITDA = 6.68 (Net Debt 24.02b / EBITDA 3.60b)
Debt / FCF = 59.61 (Net Debt 24.02b / FCF TTM 403.0m)
Total Stockholder Equity = 3.97b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.74% (Net Income -241.0m / Total Assets 31.90b)
RoE = -6.07% (Net Income TTM -241.0m / Total Stockholder Equity 3.97b)
RoCE = 13.91% (EBIT 2.18b / Capital Employed (Equity 3.97b + L.T.Debt 11.68b))
RoIC = 10.73% (NOPAT 1.72b / Invested Capital 16.03b)
WACC = 3.28% (E(4.28b)/V(29.14b) * Re(11.61%) + D(24.86b)/V(29.14b) * Rd(2.34%) * (1-Tc(0.21)))
Discount Rate = 11.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.11%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈403.0m ; Y1≈264.5m ; Y5≈120.7m
Fair Price DCF = N/A (negative equity: EV 3.85b - Net Debt 24.02b = -20.18b; debt exceeds intrinsic value)
EPS Correlation: 39.18 | EPS CAGR: 236.4% | SUE: 0.16 | # QB: 0
Revenue Correlation: 47.79 | Revenue CAGR: 2.76% | SUE: -0.48 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.15 | Chg30d=+0.020 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=0.34 | Chg30d=+0.085 | Revisions Net=-3 | Growth EPS=+131.0% | Growth Revenue=+2.6%